Cargando...
A case of checkpoint inhibitor-induced celiac disease
BACKGROUND: Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also bein...
Gardado en:
| Publicado en: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683380/ https://ncbi.nlm.nih.gov/pubmed/31383006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0694-x |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|